Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen Peptide Vaccine Combined With Targeted Drugs in EGFR-mutant NSCLC
NCT04487093Phase 1Unknown
- Sponsor
- People's Hospital of Shijiazhuang
- Start
- May 2020
- Primary completion
- May 2022
- Countries
- 1
01
Overview
Phase 1, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by People's Hospital of Shijiazhuang. Primary endpoint: Adverse events evaluated and graded according to NCI CTCAE v4.03 at 24 months. Status: unknown.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04487093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04487093.